Deca-Durabolin

(Nandrolone Decanoate)

ApprovedSmall molecule

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Deca-Durabolin is one of 67 small molecule programs targeting Malnutrition. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

MalnutritionActive, not recruiting

Dialysis PatientsCompleted

PropranololUnknown status

SarcopeniaRecruiting

Total Hip ArthroplastyNot yet recruiting

TestosteroneNot yet recruiting

MalnutritionPreclinical

Active, not recruiting

Dialysis PatientsPreclinical

Completed

PropranololPreclinical

Unknown status

SarcopeniaPhase 2

Recruiting

Total Hip ArthroplastyApproved

Not yet recruiting

TestosteroneApproved

Not yet recruiting

Competition

Competitive Landscape

30 competitors in Total Hip Arthroplasty

#DrugCompanyPhaseTrials

Cyklokapron

JJ Molner

Approved

13 2

Medrol

Pfizer

Approved

1 3

Toradol

Roche

Approved

1 4

Naropin

FFresenius Kabi USA, LLC

Approved

9 5

Zometa

Pfizer

Approved

1 6

Fragmin

Pfizer

Approved

1 7

Decadron

AAspen Global Incorporated

Approved

5 8

Marcaine

IInnocoll

Approved

5 9

Xylocaine

MMEDRx USA, Inc.

Approved

4 10

Tylenol

KKenvue Brands

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Sarcopenia

NCT05978206

Post-ApprovalNot yet recruiting

Testosterone

NCT06462482

Post-ApprovalNot yet recruiting

Total Hip Arthroplasty

NCT06608914

Clinical

Trials by Indication[1]

Testosterone1 trial

Peri-Operative Testosterone Administration in Primary Hip Arthroscopy

Not yet recruiting·AAmerican Hip Institute·Phase 4·NCT06462482·60 enrolled

Malnutrition1 trial

Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer

Completed·—·N/A·NCT03263520·60 enrolled

Sarcopenia1 trial

Study of the Effectiveness of Treatment of Sarcopenia With the Use of a Medicinal Product (Nandrolone), Comprehensive Physiotherapy and Diet

Recruiting·NNational Institute of Geriatrics, Rheumatology and Rehabilitation, Poland·Phase 2·NCT05978206·168 enrolled

Hip Fracture1 trial

Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.

Completed·MMorten Tange Kristensen PT, PhD·Phase 2·NCT03545347·29 enrolled

Propranolol1 trial

Anabolic Steroid and Propranolol in Paediatric Burn

Unknown status·KKing Edward Medical University·N/A·NCT05805553·114 enrolled

4 more indications

Dialysis Patients1 trial

Anabolic Steroids and Exercise in Hemodialysis Patients

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00250536·80 enrolled

Treatment1 trial

Nandrolone Decanoate in the Treatment of Telomeropathies

Completed·UUniversity of Sao Paulo·Phase 1/2·NCT02055456·20 enrolled

Total Hip Arthroplasty1 trial

Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty

Not yet recruiting·AAmerican Hip Institute·Phase 4·NCT06608914·60 enrolled

Weight loss1 trial

A Study to Evaluate the Effect of Nandrolone Decanoate in Women With HIV-Associated Weight Loss

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000854·38 enrolled

Regulatory

FDA Approval Timeline[4]

Jun 12, 1986

DECA-DURABOLIN

NDA NDA013132

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Nandrolone Decanoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nandrolone Decanoate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nandrolone Decanoate. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA013132). U.S. Food & Drug Administration.
[5]
SEC EDGAR — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Deca-Durabolin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Testosterone1 trial

Malnutrition1 trial

Sarcopenia1 trial

Hip Fracture1 trial

Propranolol1 trial

Dialysis Patients1 trial

Treatment1 trial

Total Hip Arthroplasty1 trial

Weight loss1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News